Because we did not observe any correlation of IFIT3 expression and the ER/PGR/HER2 status of cancer cells, we suggest that IFIT3 expression be tested regardless of ER/PGR/HER2 status if innate immunity activators will be used. This evidence concerns the gene ERBB2 and cancer.